IO-IO and IO-TKI treatments could improve 5-year survival rate for aRCC VJOncology 0:34 1 year ago 59 Далее Скачать
Dr Singer on the Efficacy of IO/TKI Doublets in Advanced RCC OncLive 2:56 1 month ago 68 Далее Скачать
IO/IO, IO/TKI Therapy for nccRCC and Its Effect on Next-Line Treatment GU Oncology Now 6:15 1 month ago 42 Далее Скачать
Frontline RCC Treatment Selection: IO/IO Versus IO/TKI GU Oncology Now 9:16 10 months ago 310 Далее Скачать
Patient Selection for IO/IO Versus IO/TKI in the Frontline Setting GU Oncology Now 7:57 1 year ago 165 Далее Скачать
Immunotherapy combined with new treatments suggested as the future of aRCC therapy VJOncology 0:31 1 year ago 84 Далее Скачать
Dr Singer on Toxicities Associated With First-Line IO/TKI Regimens in RCC OncLive 1:50 2 weeks ago 56 Далее Скачать
Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and More GU Oncology Now 8:15 1 year ago 226 Далее Скачать
Treatment ovarian cancer with novel targeted therapies and IO VJOncology 3:56 1 year ago 373 Далее Скачать
The Latest Data on IO/TKI Versus IO/IO in Frontline RCC GU Oncology Now 6:45 10 months ago 92 Далее Скачать
Dr. Pedro Barata on aRCC Diagnosis, Treatment Options, and Progression After ICI Combinations GU Oncology Now 10:29 1 year ago 101 Далее Скачать
TKI and checkpoint inhibitor combinations for kidney cancer: the IMmotion151 trial VJOncology 2:02 6 years ago 148 Далее Скачать
